The Emergence of Human Monkeypox Amid the COVID-19 Pandemic: Fears of a New Pandemic

Rasoul Raesi¹,²,*

¹Department of Nursing, Torbat Jam Faculty of Medical Sciences, Torbat Jam, Iran
²PhD in Health Services Management, Mashhad University of Medical Sciences, Mashhad, Iran

© 2024 The Author(s). Published by Bentham Open. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Address correspondence to this author at the PhD in Health Services Management, Mashhad University of Medical Sciences, Mashhad, Iran; Tel: 9157105007; E-mail: raesi.br881@gmail.com


Dear Editor,

Monkeypox is a newly emerging viral disease that has recently affected the lives of many people in various countries and has sparked widespread concern. One of the worries regarding this virus is that it will trigger a new pandemic during the COVID-19 outbreak. In this article, we will investigate the concerns surrounding the outbreak of human monkeypox during the COVID-19 pandemic.

On December 31, 2019, China notified the World Health Organization (WHO) of the outbreak of a disease with acute pneumonia presentations in Wuhan, China [1]. Within a short while, the disease caused by the new coronavirus (COVID-19) spread from China to other countries, posing a variety of health, socioeconomic, and political challenges to the world population [2, 3]. After the increase in cases and global spread of the virus, on January 30, 2020, the WHO declared the new coronavirus outbreak a pandemic and a public health emergency, with threats not only to China but to all nations [4]. According to the latest data, the total number of COVID-19 cases in Iran is 7,627,863, and the total number of deaths is 146,837 as of April 13, 2024. Globally, as of May 25, 2024, there have been 750,000,000 confirmed cases of COVID-19 and 6,500,000 deaths reported to WHO [5-8].

During 2018–2021, human cases were recognized and confirmed in six African countries, with most detected in the Democratic Republic of the Congo (DRC) and Nigeria [16-18]. In eight instances, patients with monkeypox were identified in four countries outside of Africa after traveling from Nigeria [18, 19]. The global outbreak that began in May 2022 has further highlighted the need for improvements in laboratory-based surveillance and access to treatments and vaccines to prevent and contain the infection, including in areas of Africa with endemic monkeypox [11-14].

During 2018-2021, human cases were recognized and confirmed in six African countries, with most detected in the Democratic Republic of the Congo (DRC) and Nigeria [16-18]. In eight instances, patients with monkeypox were identified in four countries outside of Africa after traveling from Nigeria [18, 19]. The global outbreak that began in May 2022 has further highlighted the need for improvements in laboratory-based surveillance and access to treatments and vaccines to prevent and contain the infection, including in areas of Africa with endemic monkeypox [11-14].

The prevention of monkeypox is regarded as one of the most crucial aspects of controlling this infectious disease. Among the essential measures for preventing monkeypox are avoiding contact with sick animals or animal carcasses, avoiding direct contact and cleaning the area where sick and suspicious animals are kept, quarantining people with symptoms and suspicious contact, washing hands with soap and water or alcohol-containing solutions after suspected

zoonotic disease caused by the Monkeypox virus (MPXV), an Orthopoxvirus, with two genetic clades: clade I (more pathogenic) and clade II. Human cases have historically been reported from rural, forested areas in central and west African countries, countries reporting cases related to population migration or travel of infected people, and exposure to imported infected mammals [11-13]. The annual number of cases in Africa has risen since 2014, surpassing reports from the previous 40 years for most countries, likely due to a combination of environmental and ecological changes, animal or human movement, the cessation of routine smallpox vaccination since its eradication in 1980, improvements in disease detection and diagnosis, and genetic changes in the virus [13-15].

Dear Editor,

Monkeypox is a newly emerging viral disease that has recently affected the lives of many people in various countries and has sparked widespread concern. One of the worries regarding this virus is that it will trigger a new pandemic during the COVID-19 outbreak. In this article, we will investigate the concerns surrounding the outbreak of human monkeypox during the COVID-19 pandemic.

On December 31, 2019, China notified the World Health Organization (WHO) of the outbreak of a disease with acute pneumonia presentations in Wuhan, China [1]. Within a short while, the disease caused by the new coronavirus (COVID-19) spread from China to other countries, posing a variety of health, socioeconomic, and political challenges to the world population [2, 3]. After the increase in cases and global spread of the virus, on January 30, 2020, the WHO declared the new coronavirus outbreak a pandemic and a public health emergency, with threats not only to China but to all nations [4]. According to the latest data, the total number of COVID-19 cases in Iran is 7,627,863, and the total number of deaths is 146,837 as of April 13, 2024. Globally, as of May 25, 2024, there have been 750,000,000 confirmed cases of COVID-19 and 6,500,000 deaths reported to WHO [5-8].

During 2018–2021, human cases were recognized and confirmed in six African countries, with most detected in the Democratic Republic of the Congo (DRC) and Nigeria [16-18]. In eight instances, patients with monkeypox were identified in four countries outside of Africa after traveling from Nigeria [18, 19]. The global outbreak that began in May 2022 has further highlighted the need for improvements in laboratory-based surveillance and access to treatments and vaccines to prevent and contain the infection, including in areas of Africa with endemic monkeypox [11-14].

The prevention of monkeypox is regarded as one of the most crucial aspects of controlling this infectious disease. Among the essential measures for preventing monkeypox are avoiding contact with sick animals or animal carcasses, avoiding direct contact and cleaning the area where sick and suspicious animals are kept, quarantining people with symptoms and suspicious contact, washing hands with soap and water or alcohol-containing solutions after suspected

zoonotic disease caused by the Monkeypox virus (MPXV), an Orthopoxvirus, with two genetic clades: clade I (more pathogenic) and clade II. Human cases have historically been reported from rural, forested areas in central and west African countries, countries reporting cases related to population migration or travel of infected people, and exposure to imported infected mammals [11-13]. The annual number of cases in Africa has risen since 2014, surpassing reports from the previous 40 years for most countries, likely due to a combination of environmental and ecological changes, animal or human movement, the cessation of routine smallpox vaccination since its eradication in 1980, improvements in disease detection and diagnosis, and genetic changes in the virus [13-15].
contacts, and prophylactically vaccinating individuals who have contact with livestock [20, 21]. The WHO convened an emergency meeting on May 20, 2022, to discuss the outbreak and assess the severity of the monkeypox threat. Hans Kluge, the regional director of the WHO in Europe, expressed concern that infections may spread worldwide as people gather for summer parties and festivals [22, 23]. According to the available information, the monkeypox virus is the most significant orthopox virus affecting human populations. Clinical recognition, diagnosis, and prevention remain challenging in poor, endemic areas where monkeypox is found. The epidemiology of monkeypox has been characterized by studies conducted at the end of smallpox eradication; however, new assessments are required now that routine smallpox vaccination has ended and herd immunity is waning.

Additionally, fundamental ecological studies are required to better comprehend the animal species involved in the transmission and maintenance of the virus and to inform preventative measures. After the COVID-19 pandemic and subsequent restrictions, the fear of a new pandemic has caused a great deal of anxiety among a large number of individuals [24, 25]. However, it is still questionable whether we should be concerned about a new pandemic. Although cases of this disease have been reported in many non-endemic countries of the world, and a recent suspected case has been reported in Iran, the necessary steps should be taken for early diagnosis and, if confirmed, appropriate treatment. Nevertheless, given that the disease is transmitted primarily through coarse respiratory particles (much lower transmission rate), the likelihood of a new pandemic is much lower than that of COVID-19.

In conclusion, although it is recommended that relevant institutions initiate the proper and thorough training of physicians and the general population regarding the symptoms and mode of transmission of this disease as soon as possible, it is illogical to create fear and panic among the populace. Moreover, this disease appears to be considerably more manageable and preventable than COVID-19 if the health principles are observed.

**AUTHORS’ CONTRIBUTIONS**

The author confirms sole responsibility for the following: study conception and design, data collection, analysis and interpretation of results, and manuscript preparation.

**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus Disease</td>
</tr>
<tr>
<td>MPXV</td>
<td>Monkeypox Virus</td>
</tr>
<tr>
<td>DRC</td>
<td>Democratic Republic of the Congo</td>
</tr>
</tbody>
</table>

**CONFLICT OF INTEREST**

The author declares no conflict of interest.

**ACKNOWLEDGEMENTS**

Declared none.

**REFERENCES**


PMID: 32185368


http://dx.doi.org/10.1016/j.ijantimicag.2020.105946 PMID: 32199877


http://dx.doi.org/10.1016/j.ijantimicag.2020.105924 PMID: 32081636


http://dx.doi.org/10.1016/j.imj.2023.08.005 PMID: 38205179


http://dx.doi.org/10.1016/S1473-3099(22)00354-1 PMID: 35636447


PMID: 4340218


http://dx.doi.org/10.15585/mmwr.mm7203a4 PMID: 36656790


http://dx.doi.org/10.1007/s11010-022-04657-0 PMID: 36626099


http://dx.doi.org/10.3389/fmed.2023.1157607 PMID: 37345798


http://dx.doi.org/10.1016/j.amsu.2022.10.007 PMID: 37363539


http://dx.doi.org/10.1016/j.ijantimicag.2023.11.001 PMID: 38205182

The Emergence of Human Monkeypox Amid the COVID-19 Pandemic

---


